| Literature DB >> 30949361 |
Sare Safi1, Hamid Ahmadieh1, Marzieh Katibeh2,3, Mehdi Yaseri1,4, Homayoun Nikkhah1,5, Saeed Karimi1,5, Ramin Nourinia1, Ali Tivay6, Mohammad Zareinejad6, Mohsen Azarmina1, Alireza Ramezani2, Siamak Moradian2, Mohammad Hossein Dehghan2, Narsis Daftarian7, Davood Abbasi8, Afshin Eshghi Fallah1, Bahareh Kheiri1.
Abstract
PURPOSE: To model a community-based telescreening program for diabetic retinopathy (DR) in Iran and to implement a pilot project at the Iranian Diabetes Society (IDS) branch in a Tehran suburb.Entities:
Year: 2019 PMID: 30949361 PMCID: PMC6425400 DOI: 10.1155/2019/2073679
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Figure 1Patient care and referral pathway. DME: diabetic macular edema; DR: diabetic retinopathy; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; MPC: macular photocoagulation; PRP: panretinal photocoagulation; PVA: presenting visual acuity. P: “evidence of PRP: active PDR” or “evidence of MPC: nonresolved DME”; P: “evidence of PRP: regressed PDR” or “evidence of MPC: resolved DME.” Blue: annual rescreening; orange: nonurgent referral; red: urgent referral.
Demographic characteristics and medical data of the screened subjects.
| Parameter | Level | Statistic | Value |
|---|---|---|---|
| Age (years) | Mean ± SD | 53 ± 14 | |
| Median (range) | 56 (12–86) | ||
| ≤25 |
| 37 (6.1) | |
| 26–45 |
| 110 (18.2) | |
| 46–65 |
| 366 (60.6) | |
| >66 |
| 91 (15.1) | |
|
| |||
| Sex | Female |
| 415 (68.7) |
| Male |
| 189 (31.3) | |
|
| |||
| Type of diabetes | Type 1 |
| 49 (8.4) |
| Type 2 |
| 531 (91.6) | |
|
| |||
| Duration of diabetes (years) | Mean ± SD | 9 ± 7 | |
| Median (range) | 8 (1–36) | ||
| <10 |
| 397 (65.7) | |
| 10–20 |
| 165 (27.3) | |
| >20 |
| 42 (7) | |
|
| |||
| Hemoglobin A1C | Mean ± SD | 7.82 ± 1.6 | |
| Median (range) | 7.6 (4.8–15) | ||
| ≤7 |
| 212 (35.1) | |
| 7–7/9 |
| 116 (19.2) | |
| 8–9 |
| 164 (27.2) | |
| >9 |
| 112 (18.5) | |
|
| |||
| Current treatment | No treatment (improving life style) |
| 7 (1.2) |
| Oral medication |
| 268 (44.4) | |
| Insulin |
| 120 (19.9) | |
| Combination therapy |
| 209 (34.6) | |
N = number; SD = standard deviation. Combination therapy = oral and insulin therapies.
Results of the fundus image interpretations.
|
| |
|---|---|
|
| |
| No DR | 378 (60) |
| DR | 226 (40) |
|
| 42 (7.4) |
|
| 122 (21.6) |
|
| 36 (6.4) |
|
| 18 (3.2) |
|
| 5 (0.9) |
|
| 3 (0.5) |
|
| |
| No DME | 527 (86.3) |
| DME | 77 (13.7) |
|
| 24 (4.26) |
|
| 43 (7.6) |
|
| 9 (1.6) |
|
| 1 (0.2) |
|
| – |
DR = diabetic retinopathy; DME = diabetic macular edema; N = number; MPC = macular photocoagulation; NPDR = nonproliferative diabetic retinopathy; PRP = panretinal photocoagulation.
Classification of patients based on presenting visual acuity (PVA) and diabetic macular edema (DME).
| Category |
|
|---|---|
| 1 | 403 (70.95) |
| 2 | 112 (19.72) |
| 3 | 37 (6.51) |
| 4 | 16 (2.82) |
N = number. 1 = PVA with pinhole >20/40 and no DME or mild DME; 2 = PVA with pinhole ≤20/40 and no DME or mild DME; 3 = PVA with pinhole >20/40 and moderate or severe DME; 4 = PVA with pinhole ≤20/40 and moderate or severe DME.